Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth Files Prevnar 13 Vaccine With FDA; GSK Is Step Ahead With Synflorix In Europe

This article was originally published in The Pink Sheet Daily

Executive Summary

Wyeth is seeking a priority review for its 13-valent pneumococcal vaccine in the U.S., while GSK’s 10-valent version is approved in Europe.

You may also be interested in...



Prevnar 13's Added Strains, Extra Studies Help Insulate Pfizer's U.S. Position

By picking up serotype 19A, Pfizer's next-generation pneumococcal disease vaccine Prevnar 13 is armed to protect against the most prevalent strain of Streptococcus pneumoniae left in the U.S

Prevnar 13's Added Strains, Extra Studies Help Insulate Pfizer's U.S. Position

By picking up serotype 19A, Pfizer's next-generation pneumococcal disease vaccine Prevnar 13 is armed to protect against the most prevalent strain of Streptococcus pneumoniae left in the U.S

Pfizer's Prevnar 13 Could Gain Edge With Vaccine Panel Review

An endorsement from FDA's Vaccines and Related Biological Products Advisory Committee for Wyeth's (now Pfizer's) Prevnar 13 would be a positive step for the firm in its race against GlaxoSmithKline rival vaccine Synflorix to capture the next-generation pneumococcal vaccine market

Related Content

Topics

UsernamePublicRestriction

Register

ID001014

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel